IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC) - Galle, P; Finn, RS; Qin, S; Ikeda, M; Ducreux, M; Kim, T-Y; Kudo, M; Lim, HY; Breder, V; Merle, P; Kaseb, A; Li, D; Feng, Y-H; Verret, W; Nicholas, A; Li, L; Ma, N; Zhu, AX; Cheng, A-L (Zeitschrift für Gastroenterologie, 2021)